Structural Basis for Distinctions between Substrate and Inhibitor Specificities for Feline Immunodeficiency Virus and Human Immunodeficiency Virus Proteases
暂无分享,去创建一个
Arthur J. Olson | Garrett M. Morris | A. Olson | G. Morris | John H. Elder | Z. Beck | J. Elder | Ying-Chuan Lin | Zachary Beck | Y. Lin
[1] P. Henderson,et al. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. , 1972, The Biochemical journal.
[2] Sidney Udenfriend,et al. Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole Range , 1972, Science.
[3] F. Studier,et al. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. , 1986, Journal of molecular biology.
[4] G. Marshall,et al. A simple, continuous fluorometric assay for HIV protease. , 2009, International journal of peptide and protein research.
[5] T. Copeland,et al. Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.
[6] A. Tomasselli,et al. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.
[7] A Wlodawer,et al. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. , 1992, The Journal of biological chemistry.
[8] A Wlodawer,et al. Mutations that alter the activity of the Rous sarcoma virus protease. , 1992, The Journal of biological chemistry.
[9] A. Aiyar,et al. Modification of the megaprimer method of PCR mutagenesis: improved amplification of the final product. , 1993, BioTechniques.
[10] S. Kent,et al. Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus , 1993, Journal of virology.
[11] A. Tomasselli,et al. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. , 1994, Methods in enzymology.
[12] C. Cameron,et al. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. , 1994, The Journal of biological chemistry.
[13] A. Kaplan,et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.
[14] J. Elder,et al. Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. , 1995, Advances in virus research.
[15] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] Alexander Wlodawer,et al. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus , 1995, Nature Structural Biology.
[17] A. Wlodawer,et al. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. , 1996, Virology.
[18] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[19] K. von der Helm. Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. , 1996, Biological chemistry.
[20] A Wlodawer,et al. Programming the Rous Sarcoma Virus Protease to Cleave New Substrate Sequences (*) , 1996, The Journal of Biological Chemistry.
[21] Andrew Carr,et al. HIV protease inhibitors , 1996, AIDS.
[22] A. Wlodawer,et al. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. , 1997, Biochemistry.
[23] A continuous fluorometric assay for the feline immunodeficiency virus protease. , 1997, Analytical biochemistry.
[24] W. Meutermans,et al. Rapid in situ neutralization protocols for Boc and Fmoc solid-phase chemistries. , 1997, Methods in enzymology.
[25] J. Ermolieff,et al. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. , 1997, Biochemistry.
[26] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .
[27] M. Malim,et al. Workshop Summary: Lessons from the Cat: Feline Immunodeficiency Virus as a Tool to Develop Intervention Strategies against Human Immunodeficiency Virus Type 1 , 1998 .
[28] N. Pedersen,et al. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. , 1998, AIDS research and human retroviruses.
[29] B. Torbett,et al. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Pettit,et al. The regulation of sequential processing of HIV-1 Gag by the viral protease. , 1998, Advances in experimental medicine and biology.
[31] J. Falloon,et al. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] C L Brooks,et al. Methodology for protein–ligand binding studies: Application to a model for drug resistance, the HIV/FIV protease system , 1999, Proteins.
[33] P. Tebas,et al. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. , 1999, AIDS.
[34] Arthur J. Olson,et al. Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants , 1999 .
[35] Bryan Chan,et al. Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..
[36] R. Swanstrom,et al. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. , 2000, Pharmacology & therapeutics.
[37] A. Wlodawer,et al. Structural studies of FIV and HIV‐1 proteases complexed with an efficient inhibitor of FIV protease , 2000, Proteins.
[38] Arthur J. Olson,et al. Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease , 2000, Journal of Virology.
[39] A Wlodawer,et al. Structural and biochemical studies of retroviral proteases. , 2000, Biochimica et biophysica acta.
[40] Zachary Q. Beck,et al. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development. , 2000, Virology.
[41] V. Miller. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. , 2001, Journal of acquired immune deficiency syndromes.
[42] V. Miller. Resistance to Protease Inhibitors , 2001 .
[43] Zachary Q. Beck,et al. Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases , 2001, Journal of Virology.